Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that the
U.S. Army Edgewood Chemical Biological Center (ECBC)
Operational Toxicology Department has joined its ever-growing customer base.
John DiBella, vice president for marketing and sales of Simulations Plus, said: “We’ve been working to penetrate the environmental toxicology field for several years, and this is one of the most satisfying results of our efforts. After sending its Study Director to attend our
Introductory GastroPlus™ Simulation and Modeling Workshop
in March, the Operational Toxicology Department at the ECBC has procured multiple licenses for
for use in their research.”
Mr. DiBella added: “According to its website, the U. S. Army Edgewood Chemical Biological Center is ‘. . . the nation’s principal research and development resource for non-medical chemical and biological (CB) defense. As a critical national asset in the CB defense community, ECBC supports all phases of the acquisition life-cycle ― from basic and applied research through technology development, engineering design, equipment evaluation, product support, sustainment, field operations and demilitarization ― to address its customers’ unique requirements.’ Needless to say, we are pleased to provide additional resources to this important national security effort.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. The Company also provides a productivity tool called Abbreviate! for PCs as well as an educational software series for science students in middle and high schools known as FutureLab
. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit
Follow Us on
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
– With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are the Company’s best estimates as of this writing but that there can be no assurances that expected or anticipated results or events will actually take place, so actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the Company’s ability to maintain its competitive advantages, acceptance of new software and improved versions of its existing software by the Company’s customers, the general economics of the pharmaceutical industry, the Company’s ability to finance growth, the Company’s ability to continue to attract and retain highly qualified technical staff, the Company’s ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on the Company’s risk factors is contained in its quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.